This company has shut down. Cambium Bio is no longer operating — its last tracked round was a Post-IPO Equity in 2024.
Explore the Startup GraveyardCMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Cambium Bio has raised $1.9M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2024.
Cambium Bio's investors include AventaCell BioMedical, Georgia Research Alliance, Zhengyang Biomedical Technology, Karolis Rosickas.
Cambium Bio is headquartered in Sydney, Australia.
CMT focuses on the development and commercialization of regenerative therapies derived from novel processed human platelets.
Cambium Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Cambium Bio — Funding & Investors." VCBacked, December 5, 2024, https://www.vcbacked.co/company/cambium-bio. Accessed August 13, 2026.
VCBacked. (2024). Cambium Bio — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/cambium-bio
{{cite web |title=Cambium Bio — Funding & Investors |url=https://www.vcbacked.co/company/cambium-bio |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated